UNSPSC 51142036: Nicoboxil

This classification denotes an analgesic agent with the molecular formula C12H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GSD5B9US0W, chemically known as 3-pyridinecarboxylic acid, butoxyethyl ester but generally known as nicoboxil, which bears US NIH Compound Identifier 14866. European Medicines Agency schedules Nicoboxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09231MIG.

UNSPSC 51142036 Nicoboxil is a Commodity code representing pharmaceutical products procured by state and local health agencies, though recent solicitations tagged under this code show a much broader pharmaceutical and drug-management focus. State and local governments buy naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through this code to support community health initiatives, public health emergency response, and benefit programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The procurement activity spans health agencies operating dedicated pharmaceutical supply chains and cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and participating states.

Recent activity is concentrated in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the response deadline was July 26, 2023, and the contract includes a two-year initial term with a one-year renewal option and FEMA funding potential. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, as a market-intelligence tool to inform future procurement strategy for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. MMCAP, administered by the Minnesota Department of Administration, released an RFP on January 20, 2026, due March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson) with awards effective July 1, 2026; evaluation weighting prioritizes price competitiveness at 75 percent, with 10 percent on fixed pricing, 5 percent on administrative fee compliance and EDI capability each, and 5 percent on agreement to a 3 percent administrative fee.